Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03601260
Recruitment Status : Unknown
Verified July 2018 by Hillel Yaffe Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : July 26, 2018
Last Update Posted : July 26, 2018
Sponsor:
Information provided by (Responsible Party):
Hillel Yaffe Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of the study is to determine the percentage of cases of acute treatment with Allopurinol in gout patients who have been previously treated.

Condition or disease Intervention/treatment Phase
Gout Drug: Allopurinol Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 700 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Examine the Percentage of Cases of Acute Treatment With Allopurinol in Gout Patients as Secondary Treatment
Estimated Study Start Date : August 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Gout
MedlinePlus related topics: Gout

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Gout Patients
Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
 Drug: Allopurinol
Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Gout patients treated with Allopurinol [ Time Frame: Six months ]
    Retrospective identification through medical records of percentage of gout patients treated with Allopurinol


Secondary Outcome Measures :
  1. Patients with contraindication to Allopurinol [ Time Frame: Six months ]
    Retrospective identification through medical records of percentage of gout patients with contraindications to Allopurinol


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gout patients

Exclusion Criteria:

  • Pregnant women
  • Chronic renal failure
  • Patients with Allopurinal hypersensitivity
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03601260


Contacts
Layout table for location contacts
Contact: Fadi Khalaila, MD 972-52-3326629 khalailaf@yahoo.com

Locations
Layout table for location information
Israel
Hillel Yaffe Medical Center
Hadera, Israel, 38100
Contact: Fadi Khalaila, MD    972-52-3326629    khalailaf@yahoo.com   
Sponsors and Collaborators
Hillel Yaffe Medical Center
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT03601260    
Other Study ID Numbers: HYMC-FKH-1
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
 Allopurinol
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs